Ryvu Therapeutics Presents Preclinical Data on RVU120 and Sy

Ryvu PRMT5 inhibitors show potential best-in-class profiles, including a strong antiproliferative effect on MTAP-deleted cell lines and a good safety window...

Related Keywords

Warsaw , L67 , Poland , San Diego , California , United States , Polish , Krzysztof Brz , , Agency For Enterprise Development , Menarini Group , Warsaw Stock Exchange , Polish Agency , Enterprise Development , Ryvu Therapeutics , Chief Scientific Officer , Novel Antitumor Agents , New Targets , Drug Delivery ,